EPHA3 Gene

EPHA3 Gene

Introduction

<div class="infobox">
<div class="infobox-gene">
<div class="gene-symbol">EPHA3</div>
<div class="gene-name">Eph Receptor A3</div>
<table>
<tr><td class="label">Symbol</td><td class="value">EPHA3</td></tr>
<tr><td class="label">Full Name</td><td class="value">Eph Receptor A3</td></tr>
<tr><td class="label">Chromosome</td><td class="value">3p11.2</td></tr>
<tr><td class="label">NCBI Gene</td><td class="value">[1972](https://www.ncbi.nlm.nih.gov/gene/1972)</td></tr>
<tr><td class="label">OMIM</td><td class="value">[602335](https://www.omim.org/entry/602335)</td></tr>
<tr><td class="label">Ensembl</td><td class="value">[ENSG00000156172](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156172)</td></tr>
<tr><td class="label">UniProt</td><td class="value">[P29320](https://www.uniprot.org/uniprotkb/P29320/entry)</td></tr>
<tr><td class="label">Associated Diseases</td><td class="value">Brain development disorders, [Alzheimer's disease](/diseases/alzheimers-disease)</td></tr>
</table>
</div>
</div>

EPHA3 (Eph Receptor A3) is a member of the Eph receptor tyrosine kinase family that plays crucial roles in neural development, synaptic plasticity, and cellular communication [@liu2020]. As a receptor tyrosine kinase that binds ephrin-A ligands, EPHA3 regulates neuronal migration, axon guidance, and synaptic function [@lu2019]. The receptor is particularly important in hippocampal development and cognitive function [@zhang2020].

EPHA3 Gene

Introduction

<div class="infobox">
<div class="infobox-gene">
<div class="gene-symbol">EPHA3</div>
<div class="gene-name">Eph Receptor A3</div>
<table>
<tr><td class="label">Symbol</td><td class="value">EPHA3</td></tr>
<tr><td class="label">Full Name</td><td class="value">Eph Receptor A3</td></tr>
<tr><td class="label">Chromosome</td><td class="value">3p11.2</td></tr>
<tr><td class="label">NCBI Gene</td><td class="value">[1972](https://www.ncbi.nlm.nih.gov/gene/1972)</td></tr>
<tr><td class="label">OMIM</td><td class="value">[602335](https://www.omim.org/entry/602335)</td></tr>
<tr><td class="label">Ensembl</td><td class="value">[ENSG00000156172](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156172)</td></tr>
<tr><td class="label">UniProt</td><td class="value">[P29320](https://www.uniprot.org/uniprotkb/P29320/entry)</td></tr>
<tr><td class="label">Associated Diseases</td><td class="value">Brain development disorders, [Alzheimer's disease](/diseases/alzheimers-disease)</td></tr>
</table>
</div>
</div>

EPHA3 (Eph Receptor A3) is a member of the Eph receptor tyrosine kinase family that plays crucial roles in neural development, synaptic plasticity, and cellular communication [@liu2020]. As a receptor tyrosine kinase that binds ephrin-A ligands, EPHA3 regulates neuronal migration, axon guidance, and synaptic function [@lu2019]. The receptor is particularly important in hippocampal development and cognitive function [@zhang2020].

The [Eph-ephrin signaling system](/mechanisms/eph-ephrin-signaling) is essential for proper brain wiring during development and continues to regulate neural circuit function in the adult brain [@filosa2018]. EPHA3 is one of the key receptors in this system, with unique expression patterns and signaling properties that distinguish it from other Eph receptors.

Gene Structure and Protein Architecture

The EPHA3 gene is located on chromosome 3p11.2 and encodes a 982-amino acid transmembrane receptor protein. Like other Eph receptors, EPHA3 consists of an N-terminal ephrin-binding domain, a cysteine-rich region, two fibronectin type III repeats, a transmembrane helix, and a cytoplasmic tyrosine kinase domain.

The ephrin-binding domain of EPHA3 shows preferential binding to ephrin-A2 and ephrin-A5 ligands, with lower affinity for ephrin-A1 and ephrin-A3. This binding specificity is determined by specific residues in the ligand-binding pocket that form specific interactions with different ephrin subtypes. The binding affinity and kinetics influence the downstream signaling outcomes.

The cytoplasmic domain of EPHA3 contains multiple tyrosine phosphorylation sites that serve as docking sites for SH2 domain-containing proteins. Key phosphorylation sites include Tyr-602, Tyr-609, and Tyr-785, which regulate the recruitment of signaling molecules including Vav family proteins, Src family kinases, and adapter proteins such as GRB2.

Expression Patterns in the Brain

EPHA3 exhibits dynamic expression patterns throughout development and in adulthood. During embryonic development, EPHA3 is widely expressed in the developing brain, with particularly high levels in the ventricular zone, where neural progenitor cells are generated. This expression pattern suggests a role in regulating neuronal progenitor cell behavior.

In the developing cortex, EPHA3 is expressed in migrating neurons and radial glial cells, which serve as scaffolds for neuronal migration. The receptor regulates the proper positioning of neurons during corticogenesis, ensuring the formation of the six-layered cortical structure [@lu2019]. Disruption of EPHA3 signaling leads to cortical malformation and layering defects.

In the adult brain, EPHA3 expression persists in the [hippocampus](/brain-regions/hippocampus), particularly in the CA3 region and dentate gyrus. The hippocampus is critical for learning and memory, and EPHA3 in this region contributes to synaptic plasticity and cognitive function [@hu2020].

Role in Neuronal Migration

During brain development, neurons must migrate from their birthplaces to their final positions to form proper neural circuits. EPHA3 plays a crucial role in this process through contact-dependent repulsion mediated by ephrin-A ligands expressed on neighboring cells and radial glial fibers [@lu2019].

The mechanism of EPHA3-mediated neuronal migration involves several steps. First, EPHA3 on the migrating neuron binds to ephrin-A ligands on neighboring cells or radial glial fibers. This binding triggers EPHA3 autophosphorylation and activation. The activated receptor then recruits and activates downstream effectors that reorganize the actin cytoskeleton, leading to membrane retraction and cell repulsion.

Studies using EPHA3 knockout mice have demonstrated that the receptor is essential for proper neuronal migration in the cerebral cortex and hippocampus. These mice show heterotopic neurons (neurons in incorrect positions) and altered hippocampal architecture. The migration deficits lead to behavioral abnormalities including impaired learning and memory.

Role in Axon Guidance

EPHA3 is a key regulator of axon guidance in the developing nervous system [@chen2020]. The receptor mediates repulsive cues that guide axons to their correct targets, ensuring the formation of precise neural circuits. This function is particularly important in the establishment of topographic maps, where the position of neurons along one axis corresponds to their target selection along another axis.

In the retinotectal system, EPHA3 expression in retinal ganglion cell axons correlates with their position along the nasotemporal axis. High EPHA3-expressing axons are repelled by high ephrin-A expressing cells in the posterior tectum, while low EPHA3-expressing axons are attracted to anterior tectum. This repulsive gradient creates an orderly topographic map.

EPHA3 also plays a role in corticospinal tract development. The corticospinal tract is the major motor pathway connecting the cortex to the spinal cord, and its proper formation is essential for voluntary movement. EPHA3-mediated repulsion guides corticospinal axons to their correct targets in the brainstem and spinal cord.

Role in Synaptic Function

In the adult brain, EPHA3 continues to play important roles in synaptic function and plasticity [@nie2020]. The receptor localizes to both pre- and postsynaptic compartments, where it regulates neurotransmitter release, synaptic structure, and plasticity mechanisms.

At the postsynaptic density, EPHA3 interacts with NMDA receptors and regulates their function. NMDA receptors are critical for synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), the cellular correlates of learning and memory [@hu2020]. EPHA3 signaling modulates NMDA receptor trafficking and function, influencing the threshold for plasticity induction.

EPHA3 also regulates dendritic spine morphology through modulation of the actin cytoskeleton. The receptor influences spine number, size, and shape, which are important determinants of synaptic strength. Dysregulated EPHA3 signaling leads to spine abnormalities that correlate with cognitive deficits.

Implications in Disease

Neurodevelopmental Disorders

EPHA3 mutations have been associated with neurodevelopmental disorders including intellectual disability and autism spectrum disorder [@wang2019]. These mutations often affect the kinase domain or ligand-binding domain, leading to impaired receptor function or altered signaling. Studies have identified de novo mutations in EPHA3 in individuals with developmental disorders, suggesting a causative role.

The link between EPHA3 and neurodevelopmental disorders likely reflects the receptor's critical role in brain development. Disruption of neuronal migration, axon guidance, or synapse formation during development can have lasting effects on brain function, manifesting as cognitive and behavioral disorders in childhood and adulthood.

Alzheimer's Disease

While EPHA3 has not been as extensively studied as EPHA2 or EPHA4 in [Alzheimer's disease](/diseases/alzheimers-disease), evidence suggests it may also play a role in AD pathogenesis [@coulthard2019]. The receptor is expressed in brain regions affected by AD, and its signaling may be dysregulated in the disease state.

EPHA3 may contribute to AD through several mechanisms, including regulation of synaptic function, modulation of tau pathology, and influence on neuroinflammatory responses. The overlapping expression patterns and signaling mechanisms with other Eph receptors suggest that EPHA3 may be part of the broader Eph-ephrin dysregulation observed in AD.

Cancer

EPHA3 is expressed in various cancer types and can function as both a tumor suppressor and oncogene depending on context. In some cancers, EPHA3 expression is reduced or lost, suggesting a tumor suppressor role. In others, EPHA3 is upregulated and promotes tumor progression.

The dual role of EPHA3 in cancer reflects the complex context-dependence of Eph receptor signaling. In certain tumor types, EPHA3 activation leads to growth arrest and apoptosis, while in others, it promotes invasion and metastasis. This complexity has implications for therapeutic targeting.

Role in Neuroinflammation

EPHA3 plays a significant role in neuroinflammation, a key feature of both neurodevelopmental and neurodegenerative disorders. The receptor is expressed on microglia and astrocytes, where it modulates their inflammatory responses.

Microglial Activation

EPHA3 regulates microglial activation states through its interaction with ephrin-A ligands. Depending on context, EPHA3 signaling can promote either pro-inflammatory or anti-inflammatory responses. Studies have shown that EPHA3 influences:

• Cytokine production (IL-1β, TNF-α, IL-6)
• Phagocytic activity
• Migration and chemotaxis
• ROS production

Astrocyte Function

EPHA3 is also expressed on astrocytes, where it regulates their support functions for neurons. Astrocytic EPHA3 influences:

• Glutamate uptake
• Potassium buffering
• Metabolic support
• Response to injury

Interaction with Other AD Risk Genes

EPHA3 does not act in isolation but interacts with other AD risk genes in complex networks:

EPHA1-EPHA3 Interaction

Both EPHA1 (protective) and EPHA3 are expressed in similar brain regions and may have complementary or antagonistic functions. EPHA1 variants reduce AD risk, while EPHA3 dysregulation contributes to pathology. Understanding the interplay between these receptors may lead to novel therapeutic strategies.

EPHA3-TREM2 Interaction

Both EPHA3 and TREM2 are expressed in microglia and may cooperate in:

• Microglial phagocytosis
• Neuroinflammation modulation
• Synaptic pruning regulation

Genetic Variants and Population Studies

Studies have identified EPHA3 variants associated with various brain disorders:

| Variant Type | Associated Condition | Effect |
|--------------|---------------------|--------|
| Loss-of-function mutations | Neurodevelopmental disorders | Intellectual disability, ASD |
| Missense variants | Alzheimer's disease | Altered risk (context-dependent) |
| Expression variants | Multiple diseases | Altered expression levels |

The identification of EPHA3 variants in human disease highlights its importance in brain health and disease.

Animal Models

EPHA3 knockout mice are viable and show subtle developmental abnormalities. The most prominent phenotype is altered axon guidance in the retinotectal system, with ectopic termination of retinal ganglion cell axons in the superior colliculus [@chen2020].

Transgenic mice overexpressing EPHA3 show enhanced hippocampal development and improved performance in certain learning tasks [@zhang2020]. These mice have been used to study the cognitive effects of enhanced Eph-ephrin signaling.

AD mouse models with EPHA3 manipulation have provided insights into the receptor's role in disease pathogenesis. Crossing EPHA3 knockout mice with AD models results in accelerated cognitive deficits, while EPHA3 overexpression provides partial protection against Aβ-induced memory impairment [@wang2020].

Interactions with Other Proteins

EPHA3 interacts with numerous proteins to mediate its signaling effects:

• Vav2/Vav3: GEFs that activate Rho GTPases
• Src family kinases: Non-receptor tyrosine kinases that phosphorylate EPHA3
• GRB2: Adapter protein linking to RAS/MAPK signaling
• PI3K: Mediates survival signaling
• PLCγ: Generates second messengers for calcium signaling
• PTP1B: Protein tyrosine phosphatase that dephosphorylates EPHA3
• NMDA receptor subunits: NR2A, NR2B

Therapeutic Potential

The importance of EPHA3 in brain development and disease makes it a potential therapeutic target [@yang2020]. Several strategies have been explored:

Signaling Mechanisms

Forward Signaling Cascade

EPHA3 transduces signals through multiple downstream pathways upon ephrin ligand binding [@zhao2019]. The canonical forward signaling cascade begins with receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic domain. Key phosphorylation sites include Tyr-602, Tyr-609, and Tyr-785, which create docking sites for SH2 domain-containing signaling proteins.

The primary downstream pathways activated by EPHA3 include:

Reverse Signaling

Like other Eph receptors, EPHA3 participates in bidirectional signaling [@zhao2019]. When EPHA3-expressing cells contact ephrin-A-expressing cells, reverse signaling can be transduced into the ephrin-bearing cell. This is particularly important in:

• Neuronal guidance during development
• Synapse formation and refinement
• Cell-cell contact inhibition

Role in Adult Neurogenesis

EPHA3 continues to play important roles in the adult brain, particularly in regions where neurogenesis occurs [@liu2018]. In the subventricular zone and subgranular zone of the dentate gyrus, EPHA3 expression on neural stem cells regulates their proliferation, differentiation, and integration into existing neural circuits.

Studies have shown that EPHA3 signaling influences:

• Neural stem cell proliferation rates
• Neuronal fate determination
• Migration of newly born neurons
• Synaptic integration of adult-born neurons

Implications in Alzheimer's Disease

Synaptic Dysfunction

EPHA3 contributes to synaptic dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease) through multiple mechanisms [@kim2020]. The receptor regulates NMDA receptor function and trafficking, and dysregulated EPHA3 signaling leads to impaired long-term potentiation (LTP), a cellular correlate of learning and memory.

Studies in AD mouse models have shown that EPHA3 expression is altered in the hippocampus, with changes in both total levels and phosphorylation status [@wang2020]. These alterations correlate with deficits in spatial memory and synaptic plasticity.

Amyloid-Beta Interaction

EPHA3 signaling is affected by amyloid-beta (Aβ) pathology, a hallmark of AD [@kim2020]. Aβ exposure leads to altered EPHA3 phosphorylation and downstream signaling, contributing to synaptic vulnerability. The interaction between EPHA3 and Aβ creates a feedforward loop where Aβ disrupts EPHA3 function, which in turn exacerbates synaptic dysfunction.

Tau Pathology

EPHA3 may also influence tau pathology, another hallmark of AD. The receptor modulates kinases and phosphatases that regulate tau phosphorylation, potentially affecting the spread of tau pathology throughout the brain.

Therapeutic Implications for AD

Given EPHA3's role in AD pathogenesis, several therapeutic strategies are being explored:

Animal Models

EPHA3 knockout mice are viable and show subtle developmental abnormalities. The most prominent phenotype is altered axon guidance in the retinotectal system, with ectopic termination of retinal ganglion cell axons in the superior colliculus.

Transgenic mice overexpressing EPHA3 show enhanced hippocampal development and improved performance in certain learning tasks. These mice have been used to study the cognitive effects of enhanced Eph-ephrin signaling.

AD mouse models with EPHA3 manipulation have provided insights into the receptor's role in disease pathogenesis. Crossing EPHA3 knockout mice with AD models results in accelerated cognitive deficits, while EPHA3 overexpression provides partial protection against Aβ-induced memory impairment.

Interactions with Other Proteins

EPHA3 interacts with numerous proteins to mediate its signaling effects:

• Vav2/Vav3: GEFs that activate Rho GTPases
• Src family kinases: Non-receptor tyrosine kinases that phosphorylate EPHA3
• GRB2: Adapter protein linking to RAS/MAPK signaling
• PI3K: Mediates survival signaling
• PLCγ: Generates second messengers for calcium signaling
• PTP1B: Protein tyrosine phosphatase that dephosphorylates EPHA3
• NMDA receptor subunits: NR2A, NR2B

Cross-References

• [Eph-ephrin Signaling Pathway](/mechanisms/eph-ephrin-signaling)
• [Neuronal Migration](/mechanisms/neuronal-migration)
• [Axon Guidance](/mechanisms/axon-guidance)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Hippocampus](/brain-regions/hippocampus)
• [Cortex](/brain-regions/cortex)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Neurodevelopmental Disorders](/diseases/neurodevelopmental-disorders)

Pathway Diagram

References

See Also

• [Eph-ephrin signaling pathway](/mechanisms/eph-ephrin-signaling)
• [Axon guidance pathway](/mechanisms/axon-guidance)
• [Neuronal migration mechanism](/mechanisms/neuronal-migration)
• [Synaptic plasticity](/mechanisms/synaptic-plasticity)
• [Hippocampus](/brain-regions/hippocampus)
• [Cortex](/brain-regions/cortex)

Genetic Epidemiology

Population Studies

Genome-wide association studies (GWAS) have identified EPHA3 variants in various populations:

• European ancestry: Specific haplotypes associated with altered AD risk
• Asian populations: Different variant frequencies, potential protective alleles
• African ancestry: Underrepresented in current studies

Rare Variants

Rare EPHA3 variants have been identified in:

• Familial cases: Mutations in kinase domain causing loss of function
• Sporadic cases: De novo mutations in early-onset disease
• Modifier effects: Variants that modify severity in carriers of other AD genes

Comparative Biology

Orthologs Across Species

EPHA3 shows interesting evolutionary patterns:

| Species | Gene Name | Key Differences |
|---------|------------|------------------|
| Mouse | Epha3 | 96% identity, similar expression |
| Zebrafish | epha3a/b | Two orthologs, distinct expression |
| Drosophila | Eph receptor | Single gene, broader specificity |
| C. elegans | VAB-1 | Related family member |

Model System Insights

Studies in model systems reveal:

• Drosophila: Conserved role in axon guidance
• Zebrafish: Enables live imaging of migration
• Xenopus: Reveals developmental mechanisms

Future Directions

Research Priorities

Key questions remain:

Therapeutic Outlook

While EPHA3-targeted therapies are not yet in clinical trials for neurodegeneration, the strong biological rationale supports continued development. The greatest potential may lie in:

• Prevention: Modulating EPHA3 in at-risk individuals
• Combination therapy: Targeting EPHA3 with other AD pathways
• Personalized medicine: Selecting patients based on EPHA3 genotype

Pathway Diagram

References